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ABSTRACT 
 
 
Background: Amphetamine enhances recovery after experimental ischaemia and has shown 
promise in small clinical trials when combined with motor or sensory stimulation. Amphetamine, 
a sympathomimetic, might have haemodynamic effects in stroke patients, although limited data 
have been published. 
 
Methods: Subjects were recruited 3-30 days post ischaemic stroke into a phase II randomised 
(1:1), double blind, placebo-controlled trial. Subjects received dexamphetamine (5mg initially, 
then 10mg for 10 subsequent doses with 3 or 4 day separations) or placebo in addition to 
inpatient physiotherapy. Recovery was assessed by motor scales (Fugl-Meyer, FM), and 
functional scales (Barthel index, BI and modified Rankin score, mRS). Peripheral blood 
pressure (BP), central haemodynamics and middle cerebral artery blood flow velocity were 
assessed before, and 90 minutes after, the first 2 doses. 
 
Results: 33 subjects were recruited, age 33-88 (mean 71) years, males 52%, 4-30 (median 15) 
days post stroke to inclusion. 16 patients were randomised to placebo and 17 amphetamine. 
Amphetamine did not improve motor function at 90 days; mean (standard deviation) FM 37.6 
(27.6) vs. control 35.2 (27.8) (p=0.81). Functional outcome (BI, mRS) did not differ between 
treatment groups. Peripheral and central systolic BP, and heart rate, were 11.2 mmHg (p=0.03), 
9.5 mmHg (p=0.04) and 7 beats/minute (p=0.02) higher respectively with amphetamine, 
compared with control. A non-significant reduction in myocardial perfusion (Buckberg Index) 
was seen with amphetamine. Other cardiac and cerebral haemodynamics were unaffected.  
 
Conclusion: Amphetamine did not improve motor impairment or function after ischaemic stroke 
but did significantly increase BP and heart rate without altering cerebral haemodynamics. 
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INTRODUCTION 
 
Modern concepts in stroke recovery now include the brain’s capacity to undergo dynamic plastic 
change.1 This plasticity is exploited by rehabilitation which is effective at improving outcome, 
and it might be possible to enhance this recovery further using pharmacological means,2 an 
approach that has been referred to as ‘pharmacological rehabilitation.3, 4 
 
In experimental models cerebral ischaemia results in a catecholamine deficit, whilst drugs that 
negatively regulate central neurotransmitters, such as haloperidol, (a dopamine receptor 
antagonist), have detrimental affects on outcome in both experimental and clinical stroke.5, 6 It 
has been hypothesised that increasing catecholamines could facilitate recovery following stroke, 
and that centrally acting neurotransmitters might modulate plasticity.7, 8  
 
Amphetamine, a sympathomimetic drug, has been shown to accelerate the recovery of motor 
function in experimental models of stroke when given in conjunction with task specific practice.5, 
9, 10 However, timing and dose of administration appears important; high doses and early 
administration being associated with a poor outcome,5, 11 whilst pre-treatment with 
amphetamine led to increased ischemic insult.12 The evidence in normal subjects13-15 and in 
clinical stroke is less clear,16-27 numerous small trials, utilizing varying dosage and timing of 
treatment, showing conflicting results, overall demonstrating no evidence of benefit on motor 
recovery. Whilst treatment appears feasible and well tolerated, a trend to increased death in the 
treatment group exists on meta-anlaysis.28 As such, there is currently no evidence to support 
the routine use of amphetamine. 
 
Despite well documented systemic effects of amphetamine,29 in particular its effect of raising 
blood pressure (BP) and heart rate (HR), limited data exist regarding the effect of amphetamine 
on peripheral haemodynamics in patient with recent ischaemic stroke. One trial found that 
amphetamine increased BP and HR in stroke,30 important as hypertension is a major risk factor 
for further stroke,31 and for a poor outcome.32 Furthermore, no data exist on the effect of 
amphetamine on central or cerebral haemodynamic in this population, despite recent evidence 
that these parameters can be related to outcome in acute stroke. 33, 34 
 
We performed a phase II trial assessing the effect of amphetamine on motor function, and 
cerebral and cardiac haemodynamics. We hypothesised that amphetamine would improve 
recovery from stroke when given with physiotherapy, and sympathomimetic actions would 
increase blood pressure and heart rate, and alter cardiac haemodynamics and cerebral blood 
flow velocity. 
4 
METHODS 
 
Design 
We performed a prospective, single-centre, double-blind, randomised placebo-controlled phase 
II trial of amphetamine in patients with recent ischaemic stroke. A sample size of 42 was 
required based on an unpublished meta-analysis of 4 small trials16, 17, 19, 25 which showed a 
beneficial effect of amphetamine on motor impairment assessed as the Fugl-Meyer motor scale: 
randomisation ratio of 1:1, mean treatment difference 16.2, with standard deviation 18.8, alpha 
= 0.05 and 80% power. The study was approved by the Nottingham Local Research Committee 
(October 2001), had a Medicines and Healthcare products Regulatory Agency Clinical Trial 
Authorisation (August 2001), and International trial number (ISRCTN 36285333), and was 
performed according to the Declaration of Helsinki and the International Conference on 
Harmonisation of Good Clinical Practice guidelines. 
 
Subjects 
Previously independent (modified Rankin score, mRS <3) adult patients with recent ischaemic 
stroke (3-30 days post ictus) and motor weakness (arm and leg components of Scandinavian 
Stroke Scale, SSS < 6) were identified and enrolled from Nottingham City Hospital (NCH). 
Patients were recruited as early as possible after 3 days once they had become clinically stable. 
The principal exclusion criteria were contra-indications to amphetamine, including intracerebral 
haemorrhage, ischaemic heart disease, uncontrolled hypertension (>160/100mmHg), 
thyrotoxicosis and history of seizures; patients with dementia, coma, or pregnancy were also 
excluded. Full written informed consent was obtained from patients prior to randomisation, or 
assent taken from a relative/carer if the patient was incompetent, confused or dysphasic. 
 
Intervention 
Patients were randomised to receive either amphetamine or placebo using computerised 
minimisation on age, sex, baseline severity (SSS), and baseline Motricity Index upper extremity 
score. Dexamphetamine sulphate (initial 5mg dose followed by 10mg thereafter) or placebo was 
administered orally twice a week with alternating 3 or 4 day separations.17, 23, 24, 26, 35, 36 The 
dose of 10mg is unlikely to cause dependency or extreme vascular instability. There were a 
total of 11 doses covering a treatment period of 35 days. Treatment was given 1-2 hours before 
scheduled physiotherapy. 
 
Outcome measures 
The primary outcome was motor impairment as assessed by Fugl-Meyer (upper extremity) 
motor scale (FM) at day 90. Secondary outcomes included Motricity Index (upper limb) (MI), 
severity (SSS), Barthel Index (BI), modified Rankin Scale (mRS), extended activity of daily living 
(EADL), language skills (Sheffield screening test), cognition (mini-mental state examination), 
mood (Zung depression score), and quality of life (health state test); these were assessed at the 
end of treatment (day 35) and day 90. Discharge disposition and length of hospital stay were 
also recorded. Safety was assessed as mortality, serious adverse events (SAE), stroke 
recurrence (ischaemic or haemorrhagic), acute coronary syndrome (myocardial infarction, 
unstable angina), and symptomatic cardiac dysrhythmia during the study period. 
 
Haemodynamic measures 
Cerebral and cardiac measurements were made immediately before and 90 minutes after both 
the first (dexamphetamine 5mg) and second treatment (dexamphetamine 10mg) doses. 
Peripheral systolic and diastolic blood pressure (SBP, DBP) and heart rate (HR) were measured 
with a validated digital readout oscillometric device (Omron HEM-705CP, Illinois, US). Pulse 
pressure (PP = SBP - DBP) and rate pressure product (RPP = HR x SBP) were calculated from 
measured parameters.37 Central BP, mean arterial pressure (MAP), compliance (augmentation 
index, AI) and myocardial perfusion (Buckberg index, BUI38) were assessed by applanation 
tonometry pulse wave analysis (SphygmoCor Px, Australia) at the radial artery. Cardiac output 
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and peripheral vascular resistance were measured by Portapres (NO-TPD Biomedical 
Instrumentation, Amsterdam, Netherlands). 
 
The middle cerebral artery (MCA) was insonnated bilaterally by transcranial Doppler (Nicolet 
EME Companion, Kleimoftheim, Germany)39 and systolic flow velocity (SFV), diastolic flow 
velocity (DFV), mean flow velocity (MFV) and pulsatility index (PI) recorded. Estimated cerebral 
perfusion pressure (CPP) was calculated using a mean of contra-lateral and ipsilateral cerebral 
blood flow velocity as follows:40, 41 CPP = (MFV/(MFV – DFV)) x (MAP-DBP). 
 
All clinical measurements were performed blinded to treatment assignment, and outcome 
measures were performed blinded to haemodynamic measures and treatment. Measurements 
were not adjusted for concurrent antihypertensive therapy (as with previous studies) since this 
was very variable depending, in part, on the supervising consultant’s medical practice. 
 
Statistical methods 
Data are presented as mean (standard deviation, SD), median (interquartile range, IQR) or 
number (%), and were analysed using Fisher’s exact test, student t  test, Mann Whitney U test, 
or comparison by ANCOVA with adjustment for baseline values, as appropriate. All analyses 
were performed using SPSS (Apple Mac, version 11; SPSS Inc, Chicago, USA). Analysis was 
by intention-to-treat; significance was taken at p<0.05. 
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RESULTS 
 
Subjects 
Thirty three patients (of an intended 42) were enrolled between September 2001 and December 
2005 (figure 1); enrolment was concluded early due to the low recruitment rate. Patients were 
enrolled 15 days (range 4 - 30 days) after stroke. Patients assigned to amphetamine were more 
likely to be male than in the placebo group otherwise both groups were matched for age, 
baseline blood pressure and stroke severity (table 1). 
 
Recovery 
There was no difference between treatment groups in Fugl-Meyer scores (primary outcome) at 
day 90 (table 2). Similarly, there was no difference between groups in the secondary outcome 
measures of impairment (MI, SSS) or function (BI, mRS and EADL) at day 35 or day 90. Length 
of stay and discharge disposition did not differ between treatment groups (table 2). No 
differences were observed between the treatment groups in terms of language skills (Sheffield 
screening test), cognition (mini-mental state examination), mood (Zung depression score) or 
quality of life (health state test) (data not shown). 
 
Haemodynamic measures 
Both groups were well matched for baseline blood pressure (table 1), although patients 
assigned to placebo had a higher heart rate, whilst patients in the amphetamine group had 
higher cerebral blood flow velocities. Peripheral and central BP were 11.2/5.8 mmHg and 
9.5/6.6 mmHg higher respectively after amphetamine than placebo (table 3). Pulse pressure 
was unaffected by amphetamine. Heart rate was significantly increased by 7-9 beats/minute 
after amphetamine (table 3). Rate pressure product was increased after amphetamine, with a 
trend to a reduction in myocardial perfusion (Buckberg Index) present after the second dose of 
amphetamine (table 3). Other cardiac haemodynamics, including vessel compliance, cardiac 
output and total peripheral resistance were unaffected by amphetamine. Similarly, amphetamine 
did not significantly alter middle cerebral artery blood flow velocity or estimates of cerebral 
perfusion pressure (table 3). 
 
Safety 
No patients died during the course of the study, 1 patient each had a recurrent ischaemic stroke 
(placebo group) and transient ischaemic attack (placebo group) (table 4). There were no 
episodes of acute coronary syndrome, or symptomatic dysrhythmia or epilepsy. Serious 
adverse event rates did not differ between treatment groups (4 vs. 3, p=0.69) (table 4). 
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DISCUSSION 
 
This phase II trial set out to assess the effect of amphetamine on functional outcome and 
haemodynamic parameters in patients with recent ischaemic stroke. The primary hypothesis 
that amphetamine would reduce motor impairment was not supported. Additionally, there were 
no effects on other measures of impairment, disability, mood and quality of life. Early studies of 
amphetamine after stroke suggested motor impairment might be reduced,16, 17, 19, 25 data we 
used to power the present trial. However, more recent studies have not supported this finding. 
Taking all the studies together (including that reported here), a meta-analysis reveals no 
evidence of efficacy, standardised mean difference (SMD) 0.12 (95% CI, -0.25 to 0.50) (figure 
2a). 
 
Amphetamine is known to have powerful effects on blood pressure and heart rate in normal 
subjects; indeed, a sympathetic surge resulting in hypertension is well recognised as a cause of 
stroke when recreational doses of the drug are taken.42 Unsurprisingly, amphetamine also 
increased peripheral blood pressure and heart rate in the present study, as has been found in 
earlier trials in patients with recent stroke.22, 26 Meta-analysis of these data show that 
amphetamine increases systolic BP (weighted mean difference) by 9.3 mmHg (95% CI, 3.3 to 
15.3) (figure 2b) and HR by 7.6 beats per minute (95% CI, 1.9 to 13.4). 
 
Other haemodynamic parameters are associated with stroke in epidemiological studies43 and 
amphetamine appears to alter some of these. Central BP (rather than peripheral brachial BP) is 
more relevant to the cerebral circulation and amphetamine increased this. Rate-pressure 
product (the mathematical product of heart rate and systolic BP,44 an index of myocardial work 
and associated with a poor outcome after stroke34) was similarly increased with amphetamine. 
In parallel, the Buckberg Index (an estimate of myocardial perfusion) was decreased non 
significantly after amphetamine. Buckberg Index is affected by heart rate, with tachycardia 
resulting in shortened diastole and the potential for reduced coronary artery filling. Hence, the 
positive chronotrophic effect of amphetamine may explain, in part, a tendency for myocardial 
perfusion to decrease. 
 
Elevation of systemic blood pressure, in the presence of dysfunctional cerebral autoregulation 
(as occurs in acute ischaemic stroke), might lead to an increase in cerebral blood flow and, 
potentially, enhance recovery after stroke.33 However, despite increasing blood pressure, no 
changes in middle cerebral artery blood flow velocity or estimated cerebral perfusion pressure 
were observed with amphetamine. Changes in cerebral blood flow with amphetamine have 
been demonstrated previously,45 although these appeared to be region-specific and, therefore, 
are probably not detectable using global measures of flow and perfusion (as utilised here). 
 
The lack of effect of amphetamine on recovery may be due to a number of reasons. First, 
enrolment in this study was terminated early due to a low recruitment rate (a problem seen in 
other trials with limiting inclusion criteria24, 46) so the intended sample size was not achieved 
thereby leading to a potential type II error when viewed in the context of the pre-trial sample 
size calculation. This problem was compounded by the heterogeneous nature of recruited 
patients with widely varying impairment at baseline. Unfortunately, the limited sample size 
prevents stratification of data by prognostic baseline factors such as stroke syndrome, severity 
or time to recruitment. Furthermore, to date, no clinical study testing amphetamine in stroke has 
taken into account ischaemic lesion size or location.27 Additionally, contemporary care of 
ischaemic stroke has evolved over the recruitment period of this study, which may also have 
introduced further heterogeneity. However, the management of blood pressure in acute stroke 
has not altered during this time. Second, no single outcome measure has been used in the 
existing amphetamine trials, so the potential for meta-analysis is limited and, again, a type II 
error may be present. In keeping with this, many of the outcome measures utilised demonstrate 
ceiling effects, although some studies have excluded patients with mild weakness in an attempt 
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to overcome this.17, 21, 24, 27 Third, suboptimal dose regimes might have been tested; the regime 
utilised here (and pioneered by others17, 23, 24, 26, 35, 36) was driven by concern for potential 
adverse effects. It is possible that higher and more frequent doses are required, as tested in 
experimental models.5, 9, 47, 48 Fourth, treatment was started between 4 and 30 days after stroke 
onset. Similar studies have failed to address the issue of most favourable time to recruitment 
and the optimal therapeutic window remains to be elucidated. Finally, perhaps amphetamine 
has no overall effect on recovery, reflecting a balance between potential benefit and harm. 
Amphetamine might enhance plasticity, thus reducing impairment, whilst also increasing risk 
factors for a poor outcome. For example, elevating BP and heart rate will increase myocardial 
work load (rate-pressure product), as seen here, whilst tachycardia will reduce myocardial 
perfusion (Buckberg Index), a pattern which is likely to promote cardiac events, particularly 
since many patients with stroke have existing heart disease (whether clinical or occult). 
Although experimental data supporting the use of amphetamine, whether in animals or normal 
volunteers, has involved subjects with normal coronary vasculature,14, 15, 49 a trend to increased 
death in stroke patients has been noted previously 28 (although not seen in the present study) 
which supports this hypothesis. 
 
We did not show any benefit of amphetamine therapy on recovery after ischaemic stroke 
although a moderate treatment effect, whether beneficial or hazardous, cannot be excluded. 
Amphetamine increased peripheral and central BP, heart rate, myocardial work rate and tended 
to reduce myocardial perfusion. In contrast, it had no effect on other central haemodynamic 
measures or middle cerebral artery blood flow velocity. Combining these data with those of 
previous studies, we find no evidence that amphetamine improves motor recovery, perhaps 
because it induces potentially hazardous effect on systemic haemodynamic parameters. Any 
future trials of amphetamine should further study its effects on haemodynamic measures. 
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TABLE 1  
 
Baseline characteristics of patients. Number (%), or mean (standard deviation) 
 
Characteristic Placebo 
(n = 16) 
D-amphetamine 
(n = 17) 
Age (years)* 73 (11) 69 (12) 
Male (%)* 4 (25) 11 (65) 
Time to treatment (days) 15 (7) 15 (8) 
Clinical stroke syndrome (%)50   
     Lacunar  6 (38) 8 (47) 
     Partial anterior circulation 5 (31) 4 (24) 
     Total anterior circulation  5 (31) 5 (29) 
TOAST aetiological group (%)51   
     Small vessel disease 3 (19) 6 (35) 
     Large artery disease 2 (13) 2 (12) 
     Cardio-embolic stroke 2 (13) 4 (24) 
Previous stroke (%) 2 (13) 3 (18) 
Previous transient ischaemic attack (%) 2 (13) 2 (12) 
Diabetes mellitus (%) 3 (19) 4 (24) 
Prior hypertension (%) 5 (31) 6 (35) 
Atrial fibrillation (%) 3 (19) 4 (24) 
Baseline severity   
     Scandinavian stroke scale * 37 (14) 34 (12) 
     Motricity Index * 39 (38) 37 (37) 
Baseline haemodynamics   
     Systolic blood pressure (mmHg) * 128.8 (17.6) 130.3 (18.3) 
     Diastolic blood pressure (mmHg) 75.6 (9.4) 76.4 (14.0) 
     Heart rate (bpm) 75.0 (10.1) 70.0 (15.4) 
BPM: beats per minute. * Minimisation variables 
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TABLE 2 
 
Functional outcome by treatment group. Frequency (%), mean (standard deviation), or median 
(interquartile range); comparison by student T test,* ANCOVA with adjustment for baseline, 
Mann-Whitney U Test,† or Chi square test‡ 
 
 Placebo 
(n=16) 
D-amphetamine 
(n= 17) 
2P 
Day 35    
   Fugl-Meyer score $*  33.5 (28.2) 35.9 (26.4) 0.81 
   Motricity Index$ 46.1 (37.9) 47.5 (36) 0.26 
   Scandinavian Stroke Scale 40.2 (12.5) 39.1 (14.3) 0.33 
   Barthel Index 11.5 (7.3) 12.5 (5.8) 0.57 
   Modified Rankin Scale 3.2 (1.5) 3.5 (0.9) 0.59 
   Extended ADL * 18.1 (21.4) 14.6 (14.1) 0.58 
Day 90    
   Fugl-Meyer score *  35.2 (27.8) 37.6 (27.6) 0.81 
   Motricity Index 35.3 (40.9) 51.2 (36.8) 0.74 
   Scandinavian Stroke Scale 41.1 (13.8) 42.9 (11.8) 0.42 
   Barthel Index 12.9 (7.4) 14.3 (7.3) 0.20 
   Modified Rankin Scale 2.9 (1.4) 3.2 (1.0) 0.46 
   Extended ADL * 25.3 (25.2) 22.3 (19.9) 0.71 
Discharge disposition (%)‡    
   Institution 4 (25%) 2 (11.8%) 0.49 
   Home 8 (50%) 12 (70.6%)  
Length of stay (days)† 67 (39-93) 63 (48-92) 0.75 
ADL: Activities of Daily Living  
$ Upper extremity 
 
15 
TABLE 3 
 
Haemodynamic and cerebral blood flow measures 90 minutes following first (5mg, day 0) and 
second (10mg, day 4) doses of dexamphetamine. Mean (standard deviation), 95% confidence 
intervals (CI); comparison by ANCOVA with adjustment for baseline. 
 
 Control Dexamphetamine Difference 95% CI p 
 90 mins post 90 mins post    
Day 0      
Peripheral      
   Systolic blood pressure  124.4 (16.2) 136.8 (21.1) 11.2 1.1, 21.4 0.03 
   Diastolic blood pressure  72. 9 (7.4) 79.0 (16.2) 5.8 -3.0, 14.5 0.19 
   Pulse pressure (mmHg) 51.5 (18.7) 57.8 (16.0) 6.0 -6, 18.3 0.33 
Central      
   Systolic blood pressure  110.9 (12.6) 122.0 (19.6) 9.5 0.64, 18.3 0.04 
   Diastolic blood pressure  73.7 (7.3) 80.0 (16.1) 6.1 -2.5, 14.7 0.16 
Heart rate (bpm) 73.3 (11.4) 75.4 (17.1) 7.0 1.8, 12.6 0.02 
Rate-pressure product 9047 (1503) 10322 (2879) 1579 453, 2705 0.08 
Buckberg Index 168.9 (34.8) 170.9 (52.1) -12.8 -33.0, 7.3 0.20 
Augmentation index 130.1 (17.2) 130.7 (24.9) -2.7 -13.7, 8.3 0.62 
Ipsilateral-MCA velocity 25.6 (11.8) 29.4 (12.3) -2.3 -9.8, 5.3 0.51 
Contralateral-MCA velocity 29.7 (18.0) 30.9 (11.9) 1.3 -13.8, 16.2 0.84 
Cerebral perfusion pressure 27.2 (12.4) 40.5 (16.2) 10.5 -4.98, 25.9 0.17 
      
Day 4       
Peripheral      
   Systolic blood pressure  127.3 (25.2) 131.7 (19.2) 7.0 -3.7, 17.7 0.19 
   Diastolic blood pressure  75.1 (17.0) 77.2 (12.6) 6.8 -2.0, 16.4 0.16 
   Pulse pressure (mmHg) 52.2 (20.4) 54.5 (17.5) 0.3 -9.2, 9.8 0.95 
Central      
   Systolic blood pressure  115.4 (21.7) 118.6 (18.6) 6.6 -3.6, 16.7 0.20 
   Diastolic blood pressure  75.7 (17.1) 78.0 (12.7) 7.2 -2.3, 16.8 0.13 
Heart rate (bpm) 71.2 (10.7) 77.7 (22.6) 9.0 2.1, 15.9 0.01 
Rate-pressure product 9111 (2402) 10106 (2794) 1620 419, 2822 0.01 
Buckberg Index 166.1 (27.5) 167.4 (59.0) -19.4 -41.6, 2.9 0.09 
Augmentation index 139.8 (22.1) 134.8 (23.4) -2.2 -18.2, 13.7 0.78 
Ipsilateral-MCA velocity 25.8 (10.5) 28.5 (12.4) 3.3 -7.6, 14.2 0.40 
Contralateral-MCA velocity 37.1 (11.1) 33.3 (19.6) -0.4 -18.9, 18.2 0.97 
Cerebral perfusion pressure 27.2 (9.7) 33.8 (17.5) 3.1 -11.0,17.2 0.64 
MCA middle cerebral artery velocity
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TABLE 4 
 
Number of patients suffering serious adverse events (SAE) by treatment group. Frequency 
(%); comparison by Fisher’s Exact test. 
 
Event Placebo D-amphetamine 
Recurrent stroke 1 0 
Transient ischaemic attack 1 0 
Pneumonia 0 1 
Depression 1 1 
Venous thromboembolism 0 1 
Fall/fractured wrist 1 0 
Total patients suffering a SAE 4 3 
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Figure Legends: 
 
Figure 1: Trial Design 
 
Figure 2a: Meta-analysis of amphetamine on motor impairment: Updated forest plot 
(meta-analysis) of effect of amphetamine on improvement in motor score  
 
 
Figure 2b: Meta-analysis of amphetamine on blood pressure: 
Updated forest plot (meta-analysis) of effect of amphetamine on systolic blood pressure 
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Figure 1 
 
Screened
De 2001 - May 2006
Dexamphetamine n = 17
Day 0 and Day 4
Haemodynamics performed pre and post does
Day 35
Too ill to co-operate n = 1
Informed consent obtained
n = 33
Randomised: Amphetamine:placebo 1:1
Placebo n = 16
Day 0 and Day 4
Haemodynamics performed pre and post does
Day 35
Alive: n = 17
Full clinical assessment performed n = 16
Day 35
Alive: n = 16
Full clinical assessment performed n = 15
Day 35
Did not attend n =1
Day 90
Alive: n = 17
Full clinical assessment performed n = 15
Day 90
Alive: n = 16
Full clinical assessment performed n = 14
Day 90
Too ill to co-operate n = 1
Withdrew consent n = 1
Day 90
Too ill to co-operate n = 1
Out of area n = 1
Dexamphetamine n = 17
Day 8 to 35
9 further doses (10mg)
17 patients received all doses
Placebo n = 16
Day 8 to 35
9 further doses 
15 patients received all doses*
*One placebo group patient did not receive final dose after an episode of agitation following the 
penultimate dose
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Figure 2a 
 
 
 
Figure 2b 
 
 
